Literature DB >> 10525718

Intracapsular hip fracture: increased cortical remodeling in the thinned and porous anterior region of the femoral neck.

K L Bell1, N Loveridge, J Power, N Rushton, J Reeve.   

Abstract

It has been shown previously that the antero-inferior cortex is subjected to maximal tensile stress during a fall onto the greater trochanter. We have recently shown that in cases of femoral neck fracture, cortical thinning and porosity is greatest in the anterior and antero-inferior region of the femoral neck. To investigate whether this is due to increased remodeling, we have quantified surface-based parameters associated with Haversian remodeling in femoral neck biopsies from women with intracapsular hip fracture and post-mortem controls. Cryostat sections of chilled biopsies were reacted for either tartrate-resistant acid phosphatase (TRAP) or alkaline phosphatase (ALP) activity. Proportions of active canals were determined in each quadrant (inferior, anterior, superior, posterior) of the femoral neck. The biopsies were then embedded in methacrylate to permit histomorphometry using Goldner's and Solochrome sections. In the cases there was no significant increase in the proportion of canals undergoing remodeling in the cortex as a whole (p = 0.846), but the regional distribution of remodeling was markedly different from that in the controls. In the anterior cortex, the proportion of canals undergoing remodeling was increased by 56% (p = 0.0087); in contrast there was a relative decrease of 35% in the superior region (p = 0.0047). In the anterior cortex of cases there were 76% and 42% increases in the proportions of eroded (p = 0.019) and osteoid-bearing (p = 0.041) canals, respectively. In the superior region, the decrease in the proportion of remodeling sites was due to a marked decrease in canals with an osteoid surface (51%; p = 0.0031). Covariance analysis with cortical porosity as the dependent variable showed that porosity was significantly dependent on the regional distribution of eroded (p = 0.033) but not on the distribution of forming (p = 0.153) canals (R(2)adj = 0.51). Cellular levels of TRAP and ALP were significantly elevated in the anterior region of cases compared with the controls (TRAP 55%, p = 0.006; ALP 36%, p = 0.003). For the posterior and inferior regions there were no marked differences in cellular TRAP and ALP levels compared with control values. These data show that the increased cortical thinning and increased porosity we have previously observed in the anterior cortex in cases of hip fracture are associated with increased indices of Haversian remodeling. These findings are consistent with the hypothesis that, in cases of hip fracture, remodeling imbalance in the anterior cortex is a continuing process up to the time of fracture and is due to increased osteoclastic cellular activity associated with an osteoblastic response that is inadequate to prevent bone loss.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10525718     DOI: 10.1007/s001980050223

Source DB:  PubMed          Journal:  Osteoporos Int        ISSN: 0937-941X            Impact factor:   4.507


  18 in total

1.  Evidence for bone formation on the external "periosteal" surface of the femoral neck: a comparison of intracapsular hip fracture cases and controls.

Authors:  J Power; N Loveridge; N Rushton; M Parker; J Reeve
Journal:  Osteoporos Int       Date:  2003-02-18       Impact factor: 4.507

2.  Increase in pore area, and not pore density, is the main determinant in the development of porosity in human cortical bone.

Authors:  C David L Thomas; Sophie A Feik; John G Clement
Journal:  J Anat       Date:  2006-08       Impact factor: 2.610

Review 3.  The vertebral fracture cascade in osteoporosis: a review of aetiopathogenesis.

Authors:  A M Briggs; A M Greig; J D Wark
Journal:  Osteoporos Int       Date:  2007-01-06       Impact factor: 4.507

4.  Development of new criteria for cortical bone histomorphometry in femoral neck: intra- and inter-observer reproducibility.

Authors:  Xiao-Yu Tong; Markus Malo; Inari S Tamminen; Hanna Isaksson; Jukka S Jurvelin; Heikki Kröger
Journal:  J Bone Miner Metab       Date:  2014-02-26       Impact factor: 2.626

5.  Osteoclastic cortical erosion as a determinant of subperiosteal osteoblastic bone formation in the femoral neck's response to BMU imbalance. Effects of stance-related loading and hip fracture.

Authors:  J Power; N Loveridge; A Lyon; N Rushton; M Parker; J Reeve
Journal:  Osteoporos Int       Date:  2004-11-26       Impact factor: 4.507

6.  Increased cancellous bone in the femoral neck of patients with coxarthrosis (hip osteoarthritis): a positive remodeling imbalance favoring bone formation.

Authors:  G R Jordan; N Loveridge; J Power; M T Clarke; J Reeve
Journal:  Osteoporos Int       Date:  2003-03-05       Impact factor: 4.507

Review 7.  A structural approach to skeletal fragility in chronic kidney disease.

Authors:  Mary B Leonard
Journal:  Semin Nephrol       Date:  2009-03       Impact factor: 5.299

8.  Fourier transform infrared imaging of femoral neck bone: reduced heterogeneity of mineral-to-matrix and carbonate-to-phosphate and more variable crystallinity in treatment-naive fracture cases compared with fracture-free controls.

Authors:  Samuel Gourion-Arsiquaud; Lyudmilla Lukashova; Jon Power; Nigel Loveridge; Jonathan Reeve; Adele L Boskey
Journal:  J Bone Miner Res       Date:  2013-01       Impact factor: 6.741

Review 9.  Hip fracture protection by alendronate treatment in postmenopausal women with osteoporosis: a review of the literature.

Authors:  Jun Iwamoto; Yoshihiro Sato; Tsuyoshi Takeda; Hideo Matsumoto
Journal:  Clin Interv Aging       Date:  2008       Impact factor: 4.458

10.  Combination of nanoindentation and quantitative backscattered electron imaging revealed altered bone material properties associated with femoral neck fragility.

Authors:  N Fratzl-Zelman; P Roschger; A Gourrier; M Weber; B M Misof; N Loveridge; J Reeve; K Klaushofer; P Fratzl
Journal:  Calcif Tissue Int       Date:  2009-09-12       Impact factor: 4.333

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.